Cardiovascular and mortality benefits of sodium-glucose co-transporter-2 inhibitors in patients with type 2 diabetes mellitus: CVD-Real Catalonia
Jordi Real,Bogdan Vlacho,Emilio Ortega,Emilio Ortega,Joan Antoni Vallés,Manel Mata-Cases,Manel Mata-Cases,Esmeralda Castelblanco,Eric Wittbrodt,Peter Fenici,Mikhail Kosiborod,Didac Mauricio,Josep Franch-Nadal +12 more
TLDR
In this article, the authors compared the risk of several CV outcomes between new users of SGLT2i and other glucose-lowering drugs (oGLDs) in Catalonia, Spain.Abstract:
Evidence from prospective cardiovascular (CV) outcome trials in type 2 diabetes (T2DM) patients supports the use of sodium–glucose co-transporter-2 inhibitors (SGLT2i) to reduce the risk of CV events. In this study, we compared the risk of several CV outcomes between new users of SGLT2i and other glucose-lowering drugs (oGLDs) in Catalonia, Spain. CVD-REAL Catalonia was a retrospective cohort study using real-world data routinely collected between 2013 and 2016. The cohorts of new users of SGLT2i and oGLDs were matched by propensity score on a 1:1 ratio. We compared the incidence rates and hazard ratio (HR) for all-cause death, hospitalization for heart failure, chronic kidney disease, and modified major adverse CV event (MACE; all-cause mortality, myocardial infarction, or stroke). After propensity score matching, 12,917 new users were included in each group. About 27% of users had a previous history of CV disease. In the SGLT2i group, the exposure time was 60% for dapagliflozin, 26% for empagliflozin and 14% for canagliflozin. The use of SGLT2i was associated with a lower risk of heart failure (HR: 0.59; 95% confidence interval [CI] 0.47–0.74; p < 0.001), all-cause death (HR = 0.41; 95% CI 0.31–0.54; p < 0.001), all-cause death or heart failure (HR = 0.55; 95% CI 0.47–0.63; p < 0.001), modified MACE (HR = 0.62; 95% CI 0.52–0.74; p < 0.001), and chronic kidney disease (HR = 0.66; 95% CI 0.54–0.80; p < 0.001). In this large, retrospective observational study of patients with T2DM from a Catalonia, initiation of SGLT-2i was associated with lower risk of mortality, as well as heart failure and CKD.read more
Citations
More filters
Journal ArticleDOI
Anti-inflammatory role of SGLT2 inhibitors as part of their anti-atherosclerotic activity: Data from basic science and clinical trials
Lucia Scisciola,V. Cataldo,Fatemeh Taktaz,Rosaria Anna Fontanella,Ada Pesapane,Pujaita Ghosh,Martina Franzese,Armando Puocci,Antonella De Angelis,Liberata Sportiello,Raffaele Marfella,Michelangela Barbieri +11 more
TL;DR: SGLT2i may have a double benefit in terms of glycemic control and control of the atherosclerotic process at a myocardial and vascular level and elaborates on the anti-inflammatory effects of sodium-glucose co-transporter 2 inhibitors on atherosclerosis.
Journal ArticleDOI
The Impact of Novel Anti-Diabetic Medications on CV Outcomes: A New Therapeutic Horizon for Diabetic and Non-Diabetic Cardiac Patients
TL;DR: The purpose of this review is to provide the everyday clinician a detailed review of the various agents within each class with regard to their specific characteristics and the effects on MACE and cardiovascular outcomes.
Journal ArticleDOI
The Place and Value of Sodium-Glucose Cotransporter 2 Inhibitors in the Evolving Treatment Paradigm for Type 2 Diabetes Mellitus: A Narrative Review
John P.H. Wilding,Marc Evans,Kevin Fernando,José Luis Górriz,Ana Cebrian,Jane Diggle,D Hicks,June James,Philip Newland-Jones,Amar Ali,S Bain,A. da Porto,Dipesh E Patel,Adie Viljoen,David A. Wheeler,Stefano Del Prato +15 more
TL;DR: In this paper , the authors provide the latest update from the Improving Diabetes Steering Committee, including perspectives on the value of SGLT2is as cost-effective therapies within the T2DM treatment paradigm, with particular focus on the latest published evidence relating to the prevention or slowing of cardiorenal complications.
Journal ArticleDOI
Prevention of Cardiorenal Complications with Sodium–Glucose Cotransporter Type 2 Inhibitors: A Narrative Review
TL;DR: In this article , the authors summarized and discussed the evidence regarding the mechanisms of action, the efficacy and safety profiles, and the clinical guidelines on the use of the therapeutic class of SGLT2i, highlighting their role in cardiorenal prevention beyond glycemic control.
Journal ArticleDOI
Empagliflozin in the treatment of heart failure and type 2 diabetes mellitus: Evidence from several large clinical trials
TL;DR: The latest and current understanding of the management for patients with established heart failure and type 2 diabetes mellitus is summarized and contemporary treatment options, sodium-glucose co-transporter-2 inhibitor, for these particular populations are presented.
References
More filters
Journal ArticleDOI
Effects of intensive glucose lowering in type 2 diabetes
Hertzel C. Gerstein,Michael Miller,Robert P. Byington,David C. Goff,J. Thomas Bigger,John B. Buse,William C. Cushman,Saul Genuth,Faramarz Ismail-Beigi,Faramarz Ismail-Beigi,Richard H. Grimm,Jeffrey L. Probstfield,Denise G. Simons-Morton,William T. Friedewald +13 more
TL;DR: In this paper, the authors investigated whether intensive therapy to target normal glycated hemoglobin levels would reduce cardiovascular events in patients with type 2 diabetes who had either established cardiovascular disease or additional cardiovascular risk factors.
Journal ArticleDOI
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
Anushka Patel,Stephen MacMahon,John Chalmers,Bruce Neal,Laurent Billot,Mark Woodward,Mark Woodward,Michel Marre,Mark E. Cooper,Paul Glasziou,Paul Glasziou,Diederick E. Grobbee,Pavel Hamet,Stephen B. Harrap,Simon Heller,Lisheng Liu,Giuseppe Mancia,Carl Erik Mogensen,C. Y. Pan,Neil R Poulter,Anthony Rodgers,Bryan Williams,Severine Bompoint,Bastiaan E. de Galan,Bastiaan E. de Galan,Rohina Joshi,F. Travert +26 more
TL;DR: A strategy of intensive glucose control, involving gliclazide (modified release) and other drugs as required, that lowered the glycated hemoglobin value to 6.5% yielded a 10% relative reduction in the combined outcome of major macrovascular and microvascular events, primarily as a consequence of a 21%relative reduction in nephropathy.
Journal ArticleDOI
Matching as Nonparametric Preprocessing for Reducing Model Dependence in Parametric Causal Inference
TL;DR: A unified approach is proposed that makes it possible for researchers to preprocess data with matching and then to apply the best parametric techniques they would have used anyway and this procedure makes parametric models produce more accurate and considerably less model-dependent causal inferences.
Journal ArticleDOI
Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies
Nadeem Sarwar,Pei Gao,Seshasai Srk.,Reeta Gobin,Stephen Kaptoge,E Di Angelantonio,Erik Ingelsson,Debbie A Lawlor,Elizabeth Selvin,Meir J. Stampfer,Stehouwer Cda.,Sarah Lewington,Lisa Pennells,Alexander M. W. Cargill Thompson,Naveed Sattar,Ian R. White,Kausik K. Ray,John Danesh +17 more
TL;DR: A meta-analysis of individual records of diabetes, fasting blood glucose concentration, and other risk factors in people without initial vascular disease from studies in the Emerging Risk Factors Collaboration found diabetes confers about a two-fold excess risk for a wide range of vascular diseases, independently from other conventional risk factors.
Journal ArticleDOI
Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy
Vlado Perkovic,Vlado Perkovic,Meg Jardine,Meg Jardine,Bruce Neal,Bruce Neal,Bruce Neal,Severine Bompoint,Hiddo J.L. Heerspink,David M. Charytan,David M. Charytan,Robert Edwards,Rajiv Agarwal,Rajiv Agarwal,George L. Bakris,Scott Bull,Christopher P. Cannon,Christopher P. Cannon,George Capuano,Pei-Ling Chu,Dick de Zeeuw,Tom Greene,Adeera Levin,Carol A. Pollock,David C. Wheeler,Yshai Yavin,Hong Zhang,Bernard Zinman,Gary Meininger,Barry M. Brenner,Kenneth W. Mahaffey +30 more
TL;DR: In patients with type 2 diabetes and kidney disease, the risk of kidney failure and cardiovascular events was lower in the canagliflozin group than in the placebo group at a median follow-up of 2.62 years.
Related Papers (5)
Use of Sodium‐Glucose Co‐transporter 2 Inhibitors in Patients with Heart Failure and Type 2 Diabetes Mellitus: Data from the Swedish Heart Failure Registry
Peter Moritz Becher,Peter Moritz Becher,B. Schrage,B. Schrage,Giulia Ferrannini,Lina Benson,Javed Butler,Juan Jesus Carrero,Francesco Cosentino,Francesco Cosentino,Ulf Dahlström,Linda Mellbin,Linda Mellbin,Giuseppe Rosano,Gianfranco Sinagra,Davide Stolfo,Davide Stolfo,Lars H. Lund,Lars H. Lund,Gianluigi Savarese,Gianluigi Savarese +20 more